MEP28908A - Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same - Google Patents

Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same

Info

Publication number
MEP28908A
MEP28908A MEP-289/08A MEP28908A MEP28908A ME P28908 A MEP28908 A ME P28908A ME P28908 A MEP28908 A ME P28908A ME P28908 A MEP28908 A ME P28908A
Authority
ME
Montenegro
Prior art keywords
medicament
pentafluorosulfanyl
benzoylguanidine
utilization
production
Prior art date
Application number
MEP-289/08A
Other languages
Bosnian (bs)
Inventor
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP28908A publication Critical patent/MEP28908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Pentafl uorsulfanil-benzoilgvanidini, postupak za njihovu proizvodnju, njihova primjena u svojstvu lijeka ili dijagnosti čkog sredstva kao I lijek koji sadrži ova jedinjenja Pronalazak se odnosi na pentafl uorsulfanil-benzoilgvanidne formule (I) i (II) u kojima R1 R4 imaju značenja koja su navedena u zahtjevima. Ova jedinjenja su pogodna kao anti aritmijdki ljekovi sa kardioprotekti vnom komponentom za profi laksu ili liječenje srčanog infarkta, isto tako za liječenje angine pectoris. Ona inhibiraju preventi vno i patofi ziološke procese pri pojavi ishemijski indukovanih oštećenja, naročito pri pojavi ishemijski indukovanih srčanih aritmija.The invention relates to pentafluorosulfanyl-benzoylguanidines of formula (I) and (II) in which R1 and R4 have the meanings which are specified in the requirements. These compounds are suitable as antiarrhythmic drugs with a cardioprotective component for the prophylaxis or treatment of myocardial infarction, as well as for the treatment of angina pectoris. They inhibit preventive and pathophysiological processes in the occurrence of ischemically induced damage, especially in the occurrence of ischemically induced cardiac arrhythmias.

MEP-289/08A 2002-05-18 2003-05-05 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same MEP28908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10222192A DE10222192A1 (en) 2002-05-18 2002-05-18 New pentafluorosulfanylbenzoylguanidine compound useful for treating e.g. infarction, angina pectoris and stroke
PCT/EP2003/004669 WO2003097591A1 (en) 2002-05-18 2003-05-05 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same

Publications (1)

Publication Number Publication Date
MEP28908A true MEP28908A (en) 2010-10-10

Family

ID=29285565

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-289/08A MEP28908A (en) 2002-05-18 2003-05-05 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same

Country Status (29)

Country Link
EP (1) EP1509498B1 (en)
JP (1) JP4383341B2 (en)
KR (1) KR100977676B1 (en)
CN (1) CN100506791C (en)
AR (1) AR040034A1 (en)
AT (1) ATE343563T1 (en)
AU (1) AU2003242531B2 (en)
BR (1) BR0311128A (en)
CA (1) CA2486336C (en)
CY (1) CY1105867T1 (en)
DE (2) DE10222192A1 (en)
DK (1) DK1509498T3 (en)
ES (1) ES2274264T3 (en)
HK (1) HK1076095A1 (en)
HR (1) HRP20041078B1 (en)
IL (2) IL165213A0 (en)
MA (1) MA27277A1 (en)
ME (1) MEP28908A (en)
MX (1) MXPA04011497A (en)
MY (1) MY139310A (en)
NO (1) NO333288B1 (en)
PE (1) PE20040452A1 (en)
PL (1) PL209700B1 (en)
PT (1) PT1509498E (en)
RS (1) RS50772B (en)
RU (1) RU2315752C2 (en)
TW (1) TWI281467B (en)
WO (1) WO2003097591A1 (en)
ZA (1) ZA200408886B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10338554A1 (en) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
DE10353204A1 (en) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Process for the preparation of 4-pentafluorosulfanyl-benzoylguanidines
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
DE10353205A1 (en) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituted pentafluorosulfurane-benzenes, processes for their preparation and their use as valuable synthesis intermediates
DE102004043938A1 (en) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
DE102004043937A1 (en) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfurane-benzenes, processes for their preparation and their use as synthesis intermediates
JP4592819B2 (en) * 2007-02-09 2010-12-08 ファイザー・リミテッド Antiparasitic agent
UA105354C2 (en) * 2007-03-23 2014-05-12 Юби Индастриз, Лтд. Process for preparing arylsulfur pentafluorides
WO2009028514A1 (en) * 2007-08-28 2009-03-05 Ube Industries, Ltd. Method for producing pentafluorosulfanylbenzene compound and novel pentafluorosulfanylbenzene compound
JP5439745B2 (en) * 2008-05-27 2014-03-12 宇部興産株式会社 Halogenomethylpentafluorosulfanylbenzene compound and method for producing the same
JP6124015B2 (en) * 2011-12-06 2017-05-10 宇部興産株式会社 Method for producing pentafluorosulfanylbenzoic acid
CN108003034B (en) * 2017-12-26 2020-07-03 金凯(辽宁)化工有限公司 Preparation method of 2-methyl-5-amino benzotrifluoride
RU2765117C2 (en) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Use of sodium salt of diethyl ester of 4-oxo-1,4-dihydropyrazolo[5,1-c]-1,2,4-triazine-3,8-dicarboxylic acid, monohydrate as drug for treatment and prevention of late complications of diabetes mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417004A1 (en) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoroalkyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
DE19517848A1 (en) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorine-containing benzoylguanidines
DE19526381A1 (en) * 1995-07-19 1997-01-23 Hoechst Ag 4-fluoroalkyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them
GB9606015D0 (en) * 1996-03-22 1996-05-22 Rhone Poulenc Agriculture New herbicides

Also Published As

Publication number Publication date
CA2486336C (en) 2011-06-21
BR0311128A (en) 2005-03-08
RS50772B (en) 2010-08-31
JP2005526138A (en) 2005-09-02
CN100506791C (en) 2009-07-01
NO333288B1 (en) 2013-04-29
PL209700B1 (en) 2011-10-31
RU2004137115A (en) 2005-05-27
IL165213A0 (en) 2005-12-18
PE20040452A1 (en) 2004-08-18
HRP20041078B1 (en) 2013-02-28
WO2003097591A1 (en) 2003-11-27
NO20045447L (en) 2004-12-14
TW200407290A (en) 2004-05-16
AU2003242531A1 (en) 2003-12-02
RS99004A (en) 2007-04-10
ES2274264T3 (en) 2007-05-16
KR20040111635A (en) 2004-12-31
IL165213A (en) 2009-05-04
CN1653044A (en) 2005-08-10
RU2315752C2 (en) 2008-01-27
MY139310A (en) 2009-09-30
CY1105867T1 (en) 2011-02-02
MXPA04011497A (en) 2005-02-14
DE50305498D1 (en) 2006-12-07
CA2486336A1 (en) 2003-11-27
AU2003242531B2 (en) 2008-07-31
EP1509498B1 (en) 2006-10-25
PL371784A1 (en) 2005-06-27
EP1509498A1 (en) 2005-03-02
HK1076095A1 (en) 2006-01-06
PT1509498E (en) 2007-01-31
AR040034A1 (en) 2005-03-09
ZA200408886B (en) 2006-01-25
DE10222192A1 (en) 2003-11-27
MA27277A1 (en) 2005-04-01
DK1509498T3 (en) 2007-02-26
ATE343563T1 (en) 2006-11-15
HRP20041078A2 (en) 2005-04-30
TWI281467B (en) 2007-05-21
KR100977676B1 (en) 2010-08-25
JP4383341B2 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
MEP28908A (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
BR0312134A (en) Fluorinated cycloalkyl-derived benzoylguanidines and their use as medicines
CY1105115T1 (en) N-((3-OXO-2,3-DHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGLE
EA200500312A1 (en) NEW SPIROCONDENSED HINASOLINONES AND THEIR APPLICATION AS PHOSPHODYESTERES INHIBITORS
NZ592741A (en) Thiochromene derivatives as hif hydroxylase inhibitors
BR9507995A (en) Compound use of the compound intermediate pharmaceutical formulation and processes for the preparation of a compound and intermediate and for treating a condition in which there is an advantage in inhibiting the production of no from l-arginine by the action of no synthase
NO20065719L (en) Substantially pure 2 - {[2- (2-methylamino-pyrimidin-4-yl) -1H-indol-5-carbonyl] -amino} -3- (phenylpyridin-2-yl-amino) -propionic acid as an IkB kinase inhibitor.
WO2004007478A3 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use
NO20082005L (en) Synthesis of renin inhibitors comprising a cyclot addition reaction
ECSP066563A (en) PENTAFLUOROSULFANIL-BENZOILGUANIDINAS, METHOD FOR ITS PRODUCTION, ITS USE AS MEDICINES OR DIAGNOSTIC AGENTS, AND MEDICATION THAT CONTAINS THEM
BRPI0406893A (en) Acylaminothiazole derivatives, their preparation and their use as inhibitors of betaamyloid peptide production
UY28358A1 (en) DERIVATIVES OF 3- (GUANIDINOCARBONIL) HETEROCICLOS, PREPARATION PROCEDURE AND INTERMEDIATE COMPOUNDS OF THIS PROCEDURE, ITS USE AS MEDICATIONS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM.
AR026179A1 (en) BENZOILGUANIDINAS HETEROCICLICALLY REPLACED, PROCEDURE FOR PREPARATION, ITS EMPLOYMENT AS MEDICINES OR DIAGNOSTIC MEDIA AS WELL AS THE MEDICINES CONTAINING THEM
BR0314714A (en) Compounds for the treatment of alzheimer's disease
Luo et al. Synthesis and biological evaluation of Arylthiourea derivatives with antitubercular activity
BRPI0510704A (en) thienopyridazines as ikk inhibitors
BRPI0413798A (en) benzoylguanidines substituted by pentafluorsulfanylphenyl, process for their preparation, their use as a medicine or diagnosis, as well as a medicine containing them
TW200621687A (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
BR0307495A (en) Dihydro-thia-phenanthrene-carbonyl-guanidines, process for their preparation, their use as a medicine or diagnostic agent
UA88693C2 (en) Sulfonylamino(thio)carbonyl compounds
BR0302902A (en) Process for the preparation of 1- (mercaptomethyl) cyclopropanoacetic acid
NO964905L (en) Substituted benzenedicarboxylic acid diguanidides, process for their preparation, their use as drug or diagnostic, and drug containing the compound
TH77463A (en) Derivatives of 3-guanidinocarbonyl-1-heteroeryl-perroll, process of preparation and substance of this process, use of such substances as drugs. And pharmaceutical mixtures containing such substances
TH154759A (en) Saturated heterocyclic compounds with nitrogen
TH102713B (en) Cyclic 11-beta hydroxosteroid inhibitors Dehydrogenase Type I